Aurinia Pharmaceuticals Inc.: 5%+ holders

As of November 10, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Aurinia Pharmaceuticals Inc. The largest reported stake is Tang Capital Management, LLC's, at 10%. 5 filings are on record since August 13, 2025 (Schedule 13D/A, June 4, 2026).

TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies ↓

Sell to companies like Aurinia Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-26 · Reporting person: ILJIN SNT Co., Ltd. · Sole voting: 0 · Shared voting: 4,987,629 · Sole dispositive: 0 · Shared dispositive: 4,987,629 · SCHEDULE 13D/A, 2026-08-26
• Filing 2026-06-04 · Reporting person: Tang Capital Management, LLC · Sole voting: 0 · Shared voting: 13,044,106 · Sole dispositive: 0 · Shared dispositive: 13,044,106 · SCHEDULE 13D/A, 2026-06-04
• Filed 2026-03-25 · Holder: Tang Capital Management, LLC · Percent: 9.2% · SCHEDULE 13D/A
• Filed 2026-03-03 · Holder: Tang Capital Management, LLC · Percent: 9.2% · SCHEDULE 13D/A
• Filed 2025-08-13 · Holder: ILJIN SNT Co., Ltd. · Percent: 5% · SCHEDULE 13D/A

Aurinia Pharmaceuticals Inc. has 5 Schedule 13D or 13G filings on record since 2025-08-13. 1 holder's latest filing reports 5% or more of common shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Aurinia Pharmaceuticals Inc. and the warning signs.

See Aurinia Pharmaceuticals Inc.'s free Snapshot Watch Aurinia Pharmaceuticals Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Aurinia Pharmaceuticals Inc. and the records around it.

Aurinia Pharmaceuticals Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)

Want the whole picture on Aurinia Pharmaceuticals Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Aurinia Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Aurinia Pharmaceuticals Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   5 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Aurinia Pharmaceuticals Inc. by CUSIP 05156V102 and gives its principal executive office as #140, 14315 - 118 AVENUE, Edmonton (SCHEDULE 13D/A, 2026-08-26).

Source of funds (Item 3)

Since the date of Amendment No. 16 to the Schedule 13D on August 13, 2025, the Reporting Persons did not purchase any Common Shares.ILJIN SNT Co., Ltd., SCHEDULE 13D/A, 2026-08-26

Purpose of Transaction (Item 4)

Tang Capital Management, LLC

Item 4 of the Original Schedule 13D is hereby amended and restated by replacing the text thereof in its entirety with the following: The Reporting Persons' acquisition was made for investment purposes. In accordance with applicable securities laws, the Reporting Persons may, from time to time and at any time, acquire additional shares and/or other equity, debt or other securities or instruments (collectively, "Securities") of the Issuer in the open market or otherwise, and reserves the right to dispose of any or all of its Securities in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the Securities, the whole depending on market conditions, the business and prospects of the Issuer and other relevant factors.Item 4 of the SCHEDULE 13D/A filed 2026-06-04

Timeline

Swipe the table sideways to see every column.

Questions about who owns Aurinia Pharmaceuticals Inc.

Who owns Aurinia Pharmaceuticals Inc.?

On this page, one holder's latest ownership filing reports 5% or more of Aurinia Pharmaceuticals Inc.: Tang Capital Management, LLC (10%, Schedule 13D/A, filed 2026-06-04).

When did Tang Capital Management, LLC buy into Aurinia Pharmaceuticals Inc.?

The filings give report dates, not purchase dates. The earliest filing from Tang Capital Management, LLC on this page is the Schedule 13D/A, filed 2026-03-03, reporting 9.2%; its latest, Schedule 13D/A filed 2026-06-04, reports 10%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 5 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Aurinia Pharmaceuticals Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Aurinia Pharmaceuticals Inc. is mentioned again
• Find former Aurinia Pharmaceuticals Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes